


글로벌 제약사 파이프라인 분석

- Johnson & Johnson -

2022. 07.

국가신약개발사업단


• 질환별 파이프라인



Johnson & Johnson

질환분야	개수	비중
Oncology	37	39%
Immunology	20	21%
Infectious	13	14%
Neuroscience	9	10%
Cardiovascular	8	9%
Ophthalmology	5	5%
Metabolic	1	1%
Dermatology	1	1%
합계	94개	100%

• 물질별 파이프라인



Johnson & Johnson

물질	개수	비중
Antibody	34	36%
Small molecules	31	33%
N/A(Not Applicable)	10	11%
Vaccine	7	8%
Gene Therapy	4	4%
Cell Therapy	4	4%
RNA	3	3%
Peptide	1	1%
합계	94개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	ACT-132577		aprocitentan	difficult to treat hypertension	Small molecules	Endothelin receptor	Endothelin receptor antagonist	Mono	Idorsia
2	Cardiovascular	Phase 3	BAY 59-7939	Xarelto	rivaroxaban	COVID-19	Small molecules	Factor Xa	Factor Xa inhibitor	Mono	Bayer
3	Cardiovascular	Phase 3			macitentan	Pulmonary arterial hypertension	Small molecules	Endothelin receptor	Endothelin receptor antagonist	Mono	-
4	Cardiovascular	Phase 3			macitentan	Chronic thromboembolic pulmonary hypertension	Small molecules	Endothelin receptor	Endothelin receptor antagonist	Mono	-
5	Cardiovascular	Phase 3		Opsumit	macitentan	Pulmonary arterial hypertension, pediatric	Small molecules	Endothelin receptor	Endothelin receptor antagonist	Mono	-
6	Cardiovascular	Phase 3			macitentan w/ tadalafil FDC	Pulmonary arterial hypertension	Small molecules	Endothelin receptor	Endothelin receptor antagonist	Combination	-
7	Cardiovascular	Phase 3		Uptravi	selexipag	Pediatric pulmonary arterial hypertension	Small molecules	PGI2	PGI2 agonist	Mono	Nippon Shinyaku
8	Cardiovascular	Phase 2	JNJ-3093		milvexian	Prevention and Treatment of Thrombosis	Small molecules	Factor XI	Factor XI inhibitor	Mono	BMS
9	Dermatology	Phase 2			bermekimab	Hidradenitis Suppurativa	Antibody	IL-1 alpha	IL-1 alpha inhibitor	Mono	Xbiotech
10	Immunology	Registration	CNT01275	Stelara	ustekinumab	Juvenile psoriatic arthritis, pediatric	Antibody	IL-12, IL-23	IL-12, IL-23 inhibitor	Mono	-
11	Immunology	Phase 3	CNT01275	Stelara	ustekinumab	Ulcerative Colitis, pediatric	Antibody	IL-12, IL-23	IL-12, IL-23 inhibitor	Mono	-
12	Immunology	Phase 3	CNT01275	Stelara	ustekinumab	Ulcerative Colitis, pediatric	Antibody	IL-12, IL-23	IL-12, IL-23 inhibitor	Mono	-
13	Immunology	Phase 3	CNT0148	Simponi	golimumab	Ulcerative Colitis, pediatric	Antibody	TNF alpha	TNF alpha inhibitor	Mono	-
14	Immunology	Phase 3	CNT01959	Tremfya	guselkumab	Crohn's Disease (SC)	Antibody	IL-23A	IL-23A inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
15	Immunology	Phase 3	CNTO1960	Tremfya	guselkumab	Psoriatic arthritis structural damage	Antibody	IL-23A	IL-23A inhibitor	Mono	-
16	Immunology	Phase 3	CNTO1961	Tremfya	guselkumab	Ulcerative Colitis monotherapy	Antibody	IL-23A	IL-23A inhibitor	Mono	-
17	Immunology	Phase 3	CNTO1962	Tremfya	guselkumab	Psoriasis, pediatric	Antibody	IL-23A	IL-23A inhibitor	Mono	-
18	Immunology	Phase 3	CNTO1963	Tremfya	guselkumab	Crohn's disease	Antibody	IL-23A	IL-23A inhibitor	Mono	-
19	Immunology	Phase 3	M281		nipocalimab	Warm autoimmune hemolytic anemia	Antibody	FCRN	FCRN antagonist	Mono	-
20	Immunology	Phase 2	CNTO1960	Tremfya	guselkumab	Giant cell arteritis	Antibody	IL-23A	IL-23A inhibitor	Mono	-
21	Immunology	Phase 2	JNJ-2113			Psoriasis	Peptide	IL-23 receptor	IL-23 receptor antagonist	Mono	-
22	Immunology	Phase 2	JNJ-4804		guselkumab+ golimumab	Psoriatic Arthritis	Antibody			Combination	-
23	Immunology	Phase 2	JNJ-4804		guselkumab+ golimumab	Ulcerative Colitis	Antibody			Combination	-
24	Immunology	Phase 2	M281		nipocalimab	Hemolytic disease of the fetus and newborn	Antibody	FCRN	FCRN antagonist	Mono	-
25	Immunology	Phase 2	M281		nipocalimab	Sjogren's syndrome	Antibody	FCRN	FCRN antagonist	Mono	-
26	Immunology	Phase 2	M281		nipocalimab	Systemic Lupus Erythematosus	Antibody	FCRN	FCRN antagonist	Mono	-
27	Immunology	Phase 2	M281		nipocalimab	Rheumatoid Arthritis	Antibody	FCRN	FCRN antagonist	Mono	-
28	Immunology	Phase 1	JNJ-4703/ JNJ-67484703			Rheumatoid Arthritis	Antibody	N/A	N/A	Mono	-
29	Immunology	Phase 1	JNJ-9280			Inflammatory Bowel Disease	N/A	N/A	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
30	Infectious	Registration	GSK1265744	Cabenuva	cabotegravir/ rilpivirine	HIV, adolescents	Small molecules	HIV integrase	HIV integrase inhibitor	Combination	ViiV Health care
31	Infectious	Registration	VAC31518			Janssen COVID-19 vaccine	Vaccine	N/A	N/A	Mono	-
32	Infectious	Registration	VAC52150	Zabdeno+ Mvabea		Monovalent Ebola virus vaccine	Vaccine	N/A	N/A	Combination	-
33	Infectious	Phase 3	VAC18193			RSV Adult vaccine	Vaccine	RSV F protein	N/A	Mono	-
34	Infectious	Phase 3	VAC31518			Jassen COVID-19 vaccine, pediatrics	Vaccine	N/A	N/A	Mono	-
35	Infectious	Phase 3	VAC52416			Multivalent ExPEC vaccine	Vaccine	N/A	Conjugate vaccine	Mono	-
36	Infectious	Phase 3	VAC89220			HIV Px vaccine	Vaccine	N/A	N/A	Mono	-
37	Infectious	Phase 3		Remicade	infliximab	COVID-19	Antibody	TNF alpha	TNF alpha inhibitor	Mono	-
38	Infectious	Phase 2	JNJ-1802			Dengue treatment	N/A	N/A	N/A	Mono	-
39	Infectious	Phase 2	JNJ-1802			Dengue prophylaxis	N/A	N/A	N/A	Mono	-
40	Infectious	Phase 2	JNJ-3989			Hepatitis B/D Co-infection	RNA	N/A	Antisense therapy	Combination	-
41	Infectious	Phase 2	JNJ-3989			Hepatitis B	RNA	N/A	Antisense therapy	Combination	-
42	Infectious	Phase 1	Ultra Long-A cting			HIV	N/A	N/A	N/A	Mono	-
43	Metabolic	Phase 1	JNJ-75220795			Non-alcoholic steatohepatitis (NASH)	RNA	PNPLA3	PNPLA3 inhibitor	Mono	Arrowhead Pharmaceut icals
44	Neuroscience	Phase 3	JNJ-42847922		seltorexant	Adjunctive treatment for Major De pressive Disorder with insomnia symptoms	Small molecules	OX2R receptor	OX2R antagonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
45	Neuroscience	Phase 3	M281		nipocalimab	Myasthenia gravis	Antibody	FCRN	FCRN antagonist	Mono	-
46	Neuroscience	Phase 2	AM-101	Spravato	esketamine	Suicidal Ideation pedica	Small molecules	NMDA receptor	NMDA receptor antago nist	Mono	Altamira Therapeutics
47	Neuroscience	Phase 2	JNJ-1813/ JNJ-40411813			Epilepsy	Small molecules	mGluR2	mGluR2 modulator	Mono	Addex Therapeutics
48	Neuroscience	Phase 2	JNJ-2657/ JNJ-63733657			Alzheimer's dementia	Antibody	Phosphorylated tau (p-tau)	Phosphorylated tau (p-tau) inhibitor	Mono	-
49	Neuroscience	Phase 2	small molecule MGLLi			Psychiatric disorder	Small molecules	N/A	N/A	Mono	-
50	Neuroscience	Phase 2	VAC20121/ ACI-35			Alzhemier's dementia	Vaccine	Microtubule-associat ed protein tau	N/A	Mono	AC Immune
51	Neuroscience	Phase 2			aticaprant	Major Depressive Deisoder	Small molecules	Kappa opioid receptor	Kappa opioid receptor antagonist	Mono	Eli Lilly
52	Neuroscience	Phase 1	JNJ-8942			Psychiatric disorder	N/A	N/A	N/A	Mono	-
53	Oncology	Registration	JNJ-42756493	Balversa	erdafitinib	Urothelial cancer	Small molecules	FGFR	FGFR inhibitor	Mono	-
54	Oncology	Registration	JNJ-4528	Carvykti	ciltacabtagene autoleucel	Relapsed/refractory Multiple My eloma	Cell Therapy	BCMA	BCMA CAR-T	Mono	Legend
55	Oncology	Registration	JNJ-7957		Teclistamab	Relapsed/refractory Multiple My eloma	Antibody	BCMA/CD3	Bispecific antibody (BCMA, CD3 agonist)	Mono	-
56	Oncology	Registration	PCI-32765	Imbruvica	ibrutinib	Chronic graft versus host disease, pediatric	Small molecules	BTK	BTK inhibitor	Mono	Abbvie
57	Oncology	Registration	PCI-32765	Imbruvica	ibrutinib	Frontline Chronic Lymphocytic Leukemia	Small molecules	BTK	BTK inhibitor	Combination	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
58	Oncology	Registration	PCI-32765	Imbruvica	ibrutinib	Mantle Cell Lymphoma	Small molecules	BTK	BTK inhibitor	Combination	-
59	Oncology	Phase 3	JNJ-4528	Carvykti	ciltacabtagene autoleucl	Frontline Multiple Myeloma TNI	Cell Therapy	BCMA	BCMA CAR-T	Mono	Legend
60	Oncology	Phase 3	JNJ-4528	Carvykti	ciltacabtagene autoleucl	Relapsed/refractory Multiple Myeloma w/1-3 PL	Cell Therapy	BCMA	BCMA CAR-T	Mono	Legend
61	Oncology	Phase 3	JNJ-54767414	Darzalex	daratumumab	Frontline Multiple Myeloma transplant eligible	Antibody	CD38	Cytotoxic to cells expressing CD38	Mono	Genmab
62	Oncology	Phase 3	JNJ-54767414	Darzalex	daratumumab	Frontline Multiple Myeloma transplant ineligible	Antibody	CD38	Cytotoxic to cells expressing CD38	Mono	Genmab
63	Oncology	Phase 3	JNJ-54767414	Darzalex	daratumumab	Smoldering Multiple Myeloma	Antibody	CD38	Cytotoxic to cells expressing CD38	Mono	Genmab
64	Oncology	Phase 3	JNJ-56021927	Erleada	apalutamide	High risk prostate cancer	Small molecules	Androgen receptor	Androgen receptor antagonist	Mono	-
65	Oncology	Phase 3	JNJ-56021927	Erleada	apalutamide	Localized prostate cancer	Small molecules	Androgen receptor	Androgen receptor antagonist	Mono	-
66	Oncology	Phase 3	JNJ-6372	Rybrevant	amivantamab	frontline NSCLC with chemotherapy	Antibody	EGFR/c-Met	Bispecific antibody(EGFR, c-Met antagonist)+small molecules	Combination	-
67	Oncology	Phase 3	JNJ-6372	Rybrevant+lazertinib	amivantamab/lazertinib	2L NSCLC	Antibody	EGFR/c-Met, EGFR	Bispecific antibody(EGFR, c-Met antagonist), EGFR inhibitor + lazertinib	Combination	Yuhan
68	Oncology	Phase 3	JNJ-7957		teclistamab	multiple myeloma 1-3PLs	Antibody	BCMA/CD3	Bispecific antibody(BCMA, CD3 agonist)	Mono	-
69	Oncology	Phase 3	PCI-32765	Imbruvica	ibrutinib	Relapsed/refractory Mantle Cell Lymphoma	Small molecules	BTK	BTK inhibitor	Combination	Abbvie
70	Oncology	Phase 3	PCI-32765	Imbruvica	ibrutinib	Relapsed/refractory Indolant Non-Hodgkins Lymphoma	Small molecules	BTK	BTK inhibitor	Mono	Abbvie

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
71	Oncology	Phase 3	TAR-200		RIS/gemcitabine+cetrelimab	NSCLC	Small molecules	RRM	RRM inhibitor+Device	Combination	Taris Biomedical
72	Oncology	Phase 3		Rybrevant+lazertinib	amivantamab/lazertinib	NSCLC	Antibody	EGFR/c-Met, EGFR	Bispecific antibody(EGFR, c-Met antagonist), EGFR inhibitor + small molecule	Mono	Yuhan
73	Oncology	Phase 3		Zejula+Zytiga	niraparib/abiraterone acetate/prednisone	Sensitive prostate cancer metastatic castration-	Small molecules	PARP-1/2, CYP18	PARP-1/2 inhibitor, CYP17 inhibitor	Combination	Tesaro (GSK)
74	Oncology	Phase 3		Zejula+Zytiga	niraparib/abiraterone acetate/prednisone	L1 Prostate cancer metastatic castration-resistant	Small molecules	PARP-1/2, CYP18	PARP-1/2 inhibitor, CYP17 inhibitor	Combination	Tesaro (GSK)
75	Oncology	Phase 2	JNJ-42756493	Balversa	erdafitinib	Non muscle invasive bladder cancer	Small molecules	FGFR	FGFR inhibitor	Mono	Otsuka Pharmaceutical
76	Oncology	Phase 2	JNJ-42756493	Balversa	erdafitinib	Tumor agnostic	Small molecules	FGFR	FGFR inhibitor	Mono	Otsuka Pharmaceutical
77	Oncology	Phase 2	JNJ-7564		talquetamab	Relapsed/refractory Multiple Myeloma	Antibody	GPRC5D/CD3	Bispecific antibody (GPRC5D, CD3 agonist)	Mono	-
78	Oncology	Phase 2	TAR-200		RIS/gemcitabine+cetrelimab	Muscle non invasive bladder cancer	Small molecules	RRM	RRM inhibitor + Device	Combination	Taris Biomedical
79	Oncology	Phase 1	JNJ-1330			Colorectal cancer	Small molecules	JAK	JAK inhibitor	Mono	-
80	Oncology	Phase 1	JNJ-4681			Hematological malignancies	Small molecules	BTK	BTK inhibitor	Mono	-
81	Oncology	Phase 1	JNJ-6358			Solid tumor	N/A	N/A	N/A	Mono	-
82	Oncology	Phase 1	JNJ-6420			Prostate cancer	Antibody	KLK2	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
83	Oncology	Phase 1	JNJ-6617			Hematological malignancies	N/A	N/A	N/A	Mono	-
84	Oncology	Phase 1	JNJ-6633			Hematological malignancies	Small molecules	MALT1	MALT1 inhibitor	Mono	-
85	Oncology	Phase 1	JNJ-6665			Hematological malignancies	N/A	DHODH	DHODH inhibitor	Mono	-
86	Oncology	Phase 1	JNJ-8343			Prostate cancer	Antibody	KLK2/CD3	Bispecific antibody (KLK2, CD3 agonist)	Mono	Zymeworks
87	Oncology	Phase 1	JNJ-8780			Hematological malignancies	Antibody	CD3/CD22	Bispecific antibody (CD3, CD22 inhibitor)	Mono	-
88	Oncology	Phase 1	JNJ-8902			Prostate cancer	N/A	N/A	N/A	Mono	-
89	Oncology	Phase 1	JNJ-9414			Prostate cancer	Cell Therapy	KLK2	Cytotoxic to cells expressing KLK2	Mono	-
90	Ophthalmology	Phase 3	AAV-RPGR		botaretigene sparoparvovec	Retinitis pigmentosa	Gene Therapy	RPGR	RPGR activator	Mono	MeiraGTx Holdings
91	Ophthalmology	Phase 2	AAV-CNGB3		entacingene turiparvovec	Achromatopsia	Gene Therapy	CNGB3	CNGB3 activator	Mono	MeiraGTx Holdings
92	Ophthalmology	Phase 1	AAV-CNGA3		aguracingene cadoparvovec	Achromatopsia	Gene Therapy	CNGA3	CNGA3 activator	Mono	MeiraGTx Holdings
93	Ophthalmology	Phase 1	JNJ-1887			Macular Degeneration	Gene Therapy	CD59	CD59 activator	Mono	Hemera Biosciences
94	Ophthalmology	Phase 1	JNJ-7100			Diabetic Macular Oedema	N/A	N/A	N/A	Mono	N/A

자료: J&J 홈페이지, BioCentury, GlobalData